NCT01732211 - A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 15, 2013

Primary Completion Date

September 23, 2013

Study Completion Date

September 23, 2013

Conditions

Pulmonary Sarcoidosis

Interventions

BIOLOGICAL

PD 0360324

100 mg Q2W or 150 mg Q2W via intravenous infusion based on protocol determined dose escalation/de-escalation criteria; 12 weeks Active Therapy;

OTHER

Normal Saline for injection

normal saline Q2W via intravenous infusion for 12 weeks

Trial Locations (5)

Mount Sinai School Of Medicine/Mount Sinai Medical Center, New York

Medical Arts Building, Cincinnati

The Barrett Cancer Center at UC Health, Cincinnati

University Hospital, Cincinnati

Iinterstitial Lung Disease & Sarcoidosis Clinic, Cincinnati